Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 4, 2002, Pages 251-255

  Saito, Yasushi ^a   Yamada, Nobuhiro ^a   Teramoto, Tamio ^a   Itakura, Hiroshige ^a   Hata, Yoshiya ^a   Nakaya, Noriaki ^a   Mabuchi, Hiroshi ^a   Tushima, Motoo ^a   Sasaki, Jun ^a   Goto, Yuichiro ^a   Ogawa, Nobuya ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

CAS 147526 32 7; HMG CoA reductase inhibitor; Hyperlipidemia; NK 104; Pitavastatin, dose finding study, effects on total cholesterol and LDL cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; SIDE EFFECT;

EID: 0036231636     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299888     Document Type: Article

References (20)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
3. A coronary primary prevention study of Scottish men aged 45-64 years: Trial design
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I: Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
6. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
7. Prevention of coronary heart disease: Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International task force for prevention of coronary heart disease
8. Prevention of coronary heart disease and lipid-lowering therapy in Japan
9. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
10. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits
11. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs
12. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia
13. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs
14. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery
15. Enzymatic determination of total serum cholesterol
16. Multilayer film elements for clinical analysis: Applications to representative chemical determinations
17. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions
18. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
19. Efficacy of atorvastatin in primary hypercholesterolemia